Comparison · NCT01464697-ca518ca7
Oral Micronized Progesterone vs Placebo Comparator: Percentage of Women With Perceived Changes in Menstrual Flow
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Oral Micronized Progesterone vs Placebo Comparator: Percentage of Women With Perceived Changes in Menstrual Flow. Trial comparisons, record NCT01464697-ca518ca7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01464697-ca518ca7
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.722 | 0.622 | 0.804 | wilson | |
| Risk in group 2 | 0.86 | 0.772 | 0.918 | wilson | |
| Risk difference, group 1 minus group 2 | -0.138 | -0.254 | -0.0175 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.839 | 0.72 | 0.979 | log | |
| Odds ratio, group 1 over group 2 | 0.422 | 0.196 | 0.906 | log | |
| Number needed to treat, for one fewer participant with the outcome on Oral Micronized Progesterone than on Placebo Comparator | 7.23 | 3.94 | 57.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Oral Micronized Progesterone | Oral micronized progesterone is Prometrium 300 mg at bedtime daily~Oral micronized progesterone: 300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks | 65 | 90 | OG000 |
| Group 2 | Placebo Comparator | Placebo~placebo: placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks | 74 | 86 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Percentage of Women With Perceived Changes in Menstrual Flow
- Description
Menstrual flow related to progesterone therapy in perimenopause was assessed based on Women's Perceived Changes Questionnaire of changes in the experience of menstrual flow/vaginal bleeding from the Final Questionnaire.
- Time frame
- 12 weeks
- Population
- The discrepancy in the Number of Participants analyzed is due to missing data on the Final Questionnaire.
Source ClinicalTrials.gov
Trial
- Title
- Progesterone for Perimenopausal Night Sweats
- NCT number
- NCT01464697
- Phases
- PHASE3
- Conditions
- Hot Flushes, Night Sweats
- Interventions
- Oral micronized progesterone, placebo
- Lead sponsor
- University of British Columbia
- Results first posted
- 2019-12-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01464697?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01464697-ca518ca7